SCHEMBL1346515

SCHEMBL1346515

CCC1C(c2ccc(OC)cc2)Cc2ccc(OC)cc2C1Cc1ccccc1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.44
DRD1 P21728 1/20 0.44
DRD4 P21917 1/20 0.44
MTNR1A P48039 2/20 0.43
MTNR1B P49286 2/20 0.43
NQO2 P16083 1/20 0.43
CYP24A1 Q07973 2/20 0.42
CYP26A1 O43174 1/20 0.42
KDM1A O60341 4/20 0.37
MAOA P21397 4/20 0.37
MAOB P27338 4/20 0.37
HTR2A P28223 1/20 0.36
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 1/20 0.35
CACNA1S Q13698 1/20 0.35
SLC6A2 P23975 2/20 0.34
SLC6A3 Q01959 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1346104 0.85 NQO2 (0.41) MTNR1AMTNR1BNQO2KDM1AMAOA
SCHEMBL1346374 0.85 NQO2 (0.48) MTNR1AMTNR1BNQO2KDM1AMAOA
SCHEMBL12133256 0.84 NQO2 (0.43) MTNR1AMTNR1BNQO2CYP26A1KDM1A
SCHEMBL12133292 0.82 SHBG (0.44) DRD2DRD1ALDH1A1SLC6A2SLC6A3
SCHEMBL1346061 0.80 MTNR1A (0.46) MTNR1AMTNR1BNQO2CYP24A1KDM1A
SCHEMBL1346092 0.80 KDM1A (0.40) MTNR1AMTNR1BNQO2KDM1AMAOA
SCHEMBL13191560 0.80 NQO2 (0.47) MTNR1AMTNR1BNQO2CYP24A1CYP26A1
SCHEMBL12133264 0.79 NQO2 (0.42) MTNR1AMTNR1BNQO2CYP26A1MAOB
SCHEMBL1346436 0.77 NQO2 (0.41) DRD2DRD1DRD4MTNR1AMTNR1B
SCHEMBL1346637 0.76 NQO2 (0.46) MTNR1AMTNR1BNQO2KDM1AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406206-B1 TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES MSD OSS BV (NL) 2013-01-30 EP disclosed
US-8063102-B2 Tetrahydronaphthalen-2-ol derivatives N.V. ORGANON (NL) 2011-11-22 US disclosed
US-8063102-B2 Tetrahydronaphthalen-2-ol derivatives N.V. ORGANON (NL) 2011-11-22 US disclosed
US-8063102-B2 Tetrahydronaphthalen-2-ol derivatives N.V. ORGANON (NL) 2011-11-22 US disclosed
US-20100240748-A1 TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES N. V. ORGANON 2010-09-23 US disclosed
US-20100240748-A1 TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES N. V. ORGANON 2010-09-23 US disclosed
US-20100240748-A1 TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES N. V. ORGANON 2010-09-23 US disclosed
WO-2010103095-A1 TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES N.V. ORGANON (NL) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240748-A1 TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES VHL, BRCA1, TPH2 DRD2 187/4885DRD1 302/4885DRD4 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.